NADAC acquisition cost data for MOVANTIK 12.5 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00310196930 | $12.26 | 2022-01-01 | Rx |
| 57841130001 | $12.26 | 2022-01-01 | Rx |
| 00310196930 | $12.26 | 2022-01-01 | Rx |
| 57841130001 | $12.26 | 2022-01-01 | Rx |
| 00310196930 | $12.26 | 2022-01-01 | Rx |
| 57841130001 | $12.26 | 2022-01-01 | Rx |
| 00310196930 | $12.26 | 2022-01-01 | Rx |
| 57841130001 | $12.26 | 2022-01-01 | Rx |
| 00310196930 | $12.26 | 2022-01-01 | Rx |
| 57841130001 | $12.26 | 2022-01-01 | Rx |
Generic: Naloxegol Oxalate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | 56,368 | N/A |
| 2020 | $12.4M | 29,102 | 52,445 | $12.12 |
| 2021 | $93.5M | 216,628 | 55,360 | $12.66 |
| 2022 | $121.4M | 262,366 | 65,091 | $13.51 |
| 2023 | $140.6M | 297,091 | 73,045 | $13.91 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $13.0M | 27,363 | 6,485 |
| Florida | $12.7M | 26,915 | 7,237 |
| Texas | $10.2M | 20,982 | 6,028 |
| North Carolina | $7.8M | 16,111 | 4,072 |
| New York | $7.5M | 16,478 | 3,885 |
| Georgia | $6.9M | 14,683 | 3,710 |
| Pennsylvania | $5.7M | 13,107 | 3,062 |
| Kentucky | $5.2M | 10,946 | 2,653 |
| Tennessee | $4.3M | 9,022 | 2,393 |
| Ohio | $4.3M | 9,716 | 2,407 |
| Indiana | $4.2M | 8,496 | 2,068 |
| Louisiana | $3.7M | 8,323 | 2,165 |
| Arizona | $3.4M | 6,792 | 1,974 |
| Alabama | $3.4M | 7,123 | 1,930 |
| Missouri | $3.3M | 7,394 | 1,613 |
| Michigan | $3.1M | 6,543 | 1,562 |
| New Jersey | $2.9M | 6,162 | 1,585 |
| Illinois | $2.8M | 5,729 | 1,508 |
| South Carolina | $2.6M | 5,538 | 1,558 |
| Connecticut | $2.6M | 5,249 | 1,205 |
| Oklahoma | $2.5M | 5,212 | 1,374 |
| Maryland | $2.4M | 4,749 | 1,290 |
| Virginia | $2.3M | 4,470 | 1,283 |
| Colorado | $2.1M | 4,001 | 1,126 |
| Arkansas | $2.0M | 4,227 | 986 |
| Mississippi | $1.9M | 4,119 | 973 |
| Washington | $1.8M | 3,778 | 945 |
| Utah | $1.6M | 3,672 | 951 |
| Wisconsin | $1.5M | 2,947 | 712 |
| Massachusetts | $1.5M | 3,198 | 727 |
| Kansas | $1.4M | 3,187 | 622 |
| Nevada | $1.3M | 2,602 | 717 |
| Idaho | $1.1M | 2,392 | 572 |
| Nebraska | $1.0M | 2,484 | 505 |
| West Virginia | $976.7K | 2,131 | 486 |
| Minnesota | $793.2K | 1,677 | 428 |
| Iowa | $718.9K | 1,658 | 324 |
| Oregon | $711.6K | 1,372 | 394 |
| Delaware | $575.0K | 1,097 | 365 |
| New Mexico | $406.6K | 779 | 202 |
| New Hampshire | $355.5K | 748 | 203 |
| Maine | $308.0K | 488 | 154 |
| South Dakota | $285.1K | 653 | 124 |
| Montana | $271.9K | 535 | 136 |
| Wyoming | $204.1K | 433 | 95 |
| Rhode Island | $195.4K | 444 | 99 |
| Hawaii | $142.9K | 241 | 70 |
| North Dakota | $135.1K | 357 | 69 |
| Alaska | $117.3K | 239 | 52 |
| District of Columbia | $79.3K | 140 | 45 |
| Vermont | $76.9K | 124 | 39 |
| Puerto Rico | $51.8K | 117 | 29 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.